Biomarkers and Case Reports


Vaccines prevent infectious diseases, but vaccination is not without risk and adverse events are reported although they are more commonly reported for biologicals than for vaccines. Vaccines and biologicals must undergo a rigorous assessment before and after licensure to minimize safety concerns. Potential safety concerns should be identified as early as possible during the development of vaccines and biologicals to minimize investment risk. State-of-the-art tools and methods to identify safety concerns and biomarkers that are predictive of clinical outcomes are indispensable. For vaccines and adjuvant formulations, systems biology approaches, supported by single-cell microfluidics applied to translational studies between preclinical and clinical studies, could improve reactogenicity and safety predictions.


    Related Conference of Biomarkers and Case Reports

    April 18-19, 2022

    Global Summit on Vaccines and Immunology

    Madrid, Spain
    June 23-24, 2022

    35th World Congress on Vaccines and Immunization

    Bangkok, Thailand
    September 05-06, 2022

    42nd Global Summit and Expo on Vaccines & Immunology

    Paris, France
    September 15-16, 2022

    International Conference on Vaccine and Vaccine research

    Paris, France
    October 07-08, 2022

    34th International Conference on Vaccines and Immunization

    Zurich, Switzerland
    November 04-05, 2022

    34th Annual Congress on Vaccine and Clinical Trials

    Toronto, Canada

    Biomarkers and Case Reports Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in